Elaia Closes €134M DeepTech Seed Fund III as European Deep Tech Hits Escape Velocity
TL;DR
Elaia has closed its third DeepTech Seed fund at €134 million — double the size of its two predecessors and 12% above its revised €120 million target — cementing the Paris-based firm's position as one of Europe's most active and credible pre-seed and seed investors in hard science and deep tech. With over €1 billion in AUM now across vehicles and research institution partnerships spanning PSL, INRIA, and the Max Planck Foundation, Elaia is no longer just a French VC story. It is a European deep tech infrastructure play.
Key Takeaways
Doubling fund size while exceeding targets is not easy in this market. DTS1 and DTS2 each raised in the €76-77 million range. DTS3 at €134 million represents a step-change in scale achieved in a period when many European fund managers are struggling to hold previous vintages flat. That LP confidence — especially from institutions like Bpifrance, BNP Paribas, and Institut Pasteur — reflects a genuine track record, not just sector optimism.
The research institution partnership model is a genuine moat. By embedding itself with PSL, INRIA, CNRS, the Barcelona Supercomputing Centre, and the Max Planck Foundation, Elaia sees breakthrough technologies and founding teams months before most investors know they exist. That information asymmetry is structurally repeatable and nearly impossible for generalist funds to replicate. It produced Aqemia, Alice and Bob, and Mablink Bioscience — the last of which was acquired by Eli Lilly.
Three pillars across computing, industry, and life sciences creates genuine diversification. DTS3's mandate spanning AI infrastructure, cybersecurity, quantum, physical AI, robotics, biotech, and medical devices is broader than it sounds. Each pillar benefits from Europe's specific strengths: world-class research institutions, rigorous engineering talent, and a regulatory environment that is increasingly forcing US tech giants to engage with European counterparts rather than bypass them.
Elaia hitting €1B AUM marks a maturation moment for the firm. Between DTS3 closing, DV5's €120M first close, and the Lazard Elaia Capital joint venture, Elaia has crossed a threshold that fundamentally changes its institutional standing and ability to attract co-investors into portfolio rounds. This is no longer an emerging manager — it is a platform.
Why This Fund Matters
European deep tech has had a credibility problem for the better part of a decade. The region produces world-class science — routinely — but converting that science into fundable companies, and then into scaled enterprises, has required infrastructure that simply did not exist. What Elaia has spent the past several years building is exactly that infrastructure: the relationships, the expertise, and the institutional credibility to take pre-commercial science out of university labs and put serious capital behind it at the earliest possible moment.
DTS3 is the third iteration of a strategy that has now been stress-tested through full market cycles. The fund backs founders at pre-seed and seed — when the technology risk is highest, the round is smallest, and the gap between scientific achievement and investable company is largest. That is exactly where generalist funds, who lack the domain depth to evaluate the technology, tend to pull back. Elaia's research institution partnerships solve the diligence problem: when PSL or INRIA or CNRS is your co-investor and your deal flow source, you are getting access to the top of the scientific funnel with a technical filter already applied.
The €134 million close against a €120 million target also reflects something important about the fund's positioning within the broader European deep tech ecosystem. Multiple countries' governments, institutions, and private LPs — including French, Italian, and pan-European entities — came together to back this vehicle. That cross-border LP syndicate is a preview of where European VC fund formation is heading as the continent takes its strategic technology independence more seriously.
It is worth noting what Elaia is not. This is not a fund chasing the hot software narrative or applying for AI venture status to raise in a favorable market. DTS3 backs hard science: quantum computing, photonics, advanced robotics, synthetic biology, medical devices. These categories take longer to reach liquidity, but when they do — as Mablink's acquisition by Eli Lilly demonstrated — the returns can be transformative. Elaia has earned the right to make that long-duration bet with serious institutional capital.
The Team
Xavier Lazarus, Managing Partner, has been building Elaia's deep tech thesis since long before deep tech became a fashionable investment category. His emphasis on partnering with European research institutions — rather than waiting for spinouts to find investors — is a direct product of watching how the best university technology transfer outcomes have historically been sequenced. Anne-Sophie Carrese, Partner, has been instrumental in building the DTS strategy from its earliest iteration, developing the PSL partnership model that has now been replicated across Europe's leading research institutions. Together, the team now manages a platform that spans pre-seed seed (DTS), growth-stage digital ventures (DV5), and a joint venture with Lazard targeting the capital markets interface — a genuinely unusual full-stack positioning for a European VC firm.
Early Portfolio
DTS3 has already backed 11 companies including Proxima Fusion (commercial fusion energy), GetVocal (AI agents for enterprise), and Biophta (AI-assisted chronic eye disease diagnosis). From earlier Elaia deep tech vehicles, notable outcomes include Aqemia (AI-driven drug discovery), Alice and Bob (quantum computing hardware), and Mablink Bioscience, which was acquired by Eli Lilly in a transaction that returned significant capital to Elaia LPs. The early portfolio across DTS3 reflects the fund's three-pillar structure and its emphasis on companies where the science is validated before the venture funding begins.
What This Means for Founders
If you are a scientist-founder in Europe building at the intersection of hard technology and a large commercial market — quantum, synthetic biology, advanced materials, robotics, medical devices, or next-generation computing — Elaia DTS3 is actively deploying. The firm's check range of €1-13M gives it flexibility to lead your pre-seed or seed round outright, and its research institution partnerships mean the team can evaluate your technology with genuine domain depth rather than outsourcing diligence to advisors. The partnership with PSL, INRIA, CNRS, and other institutions also means Elaia can help you navigate the technology transfer and IP structures that are often the primary friction point for science-based founding teams.
Founders who are not yet incorporated but are emerging from European academic institutions should know that Elaia is explicitly designed to back companies at exactly that stage. The firm's entire reason for being is to close the gap between scientific breakthrough and venture-backed company — and DTS3 gives them the capital to do it at meaningful scale across Europe's leading research clusters.
Fund Momentum Take
Elaia crossing the €1 billion AUM threshold is a meaningful milestone, but the number that matters more is the portfolio quality. Mablink's Eli Lilly exit, Alice and Bob's continued momentum in quantum hardware, and Proxima Fusion's visibility as one of Europe's most serious fusion energy bets — these are not coincidences. They are the output of a repeatable process for identifying pre-commercial science with commercial potential and backing founders through the difficult early years when most investors are unwilling to take the technology risk.
DTS3 at €134 million is a bigger fund with a broader geographic mandate than its predecessors. That scale creates some risk — more money to deploy means higher pressure on entry valuations and portfolio construction discipline — but Elaia's check range of €1-13M still gives the team significant flexibility to calibrate ownership without overpaying for early-stage science bets.
The bigger picture here is that European deep tech is genuinely reaching an inflection point. The combination of government capital (Bpifrance, France 2030), institutional anchor LPs (BNP Paribas, Institut Pasteur), and pan-European research institution deal flow gives Elaia a structural advantage that compounds over time. We expect DTS4 to be larger still — and more interesting.
Frequently Asked Questions
What does Elaia's DeepTech Seed Fund III invest in?
DTS3 backs pre-seed and seed B2B deep tech startups across three pillars: the future of computing (AI, cybersecurity, semiconductors, quantum), the future of industry (physical AI, robotics, advanced materials, energy), and the future of life sciences (biotech, digital health, medical devices). The fund writes checks from €1 million to €13 million.
How does Elaia source deals through research institutions?
Elaia has formal partnerships with PSL Université, INRIA, CNRS, the Barcelona Supercomputing Centre, and the Max Planck Foundation. These partnerships give the firm early access to breakthrough technologies and founding teams emerging from European academic research, often before the company is formally incorporated.
Who are the key people at Elaia behind DTS3?
Xavier Lazarus is Managing Partner and the architect of Elaia's full-stack investment strategy. Anne-Sophie Carrese is the Partner leading DTS3, having built the deep tech seed strategy from its earliest iteration in partnership with PSL and other research institutions.
What notable exits has Elaia's deep tech strategy generated?
Mablink Bioscience, backed through Elaia's previous deep tech vehicles, was acquired by Eli Lilly. Other portfolio standouts include Aqemia (AI drug discovery) and Alice and Bob (quantum computing hardware), both of which continue to raise significant capital.
Is DTS3 Elaia's only active fund?
No. Elaia is simultaneously deploying DTS3 (pre-seed and seed deep tech, €134M) and DV5, its fifth Digital Venture fund which completed a €120M first close in February 2026 with a target of €300M. Together with Lazard Elaia Capital, the firm now manages over €1 billion in assets across the full technology investment lifecycle.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.